Studies on X(4260) and X(4660) particles

Studies on the X(4260) and X(4660) resonant states in an effective lagrangian approach are reviewed. Using a Breit--Wigner propagator to describe their propagation, we find that the X(4260) has a sizable coupling to the $\omega\chi_{c0}$ channel, while other couplings are found to be negligible. Besides, it couples much stronger to $\sigma$ than to $f_0(980)$: $|g_{X\Psi \sigma}^2/g^2_{X\Psi f_0(980)}|\sim O(10) \ .$ As an approximate result for X(4660), we obtain that the ratio of $\frac{Br(X\rightarrow\Lambda_c^+\Lambda_c^-)}{Br(X\rightarrow\Psi(2s)\pi^+\pi^-)}\simeq 20$. Finally, taking X(3872) as an example, we also point out a possible way to extend the previous method to a more general one in the effective lagrangian approach.Comment: Talk given by H. Q. Zheng at "Xth Quark Confinement and the Hadron Spectrum", October 8-12, 2012, TUM Campus Garching, Munich, Germany. 6 pages, 3 figures, 3 table

Pole analysis on the hadron spectroscopy of Λb→J/ΨpK−\Lambda_b\to J/\Psi p K^-

In this paper we study the $J/\Psi p$ spectroscopy in the process of $\Lambda_b\to J/\Psi p K^-$. The final state interactions of coupled channel $J/\Psi p$ ~-~ $\bar{D} \Sigma_c$~-~$\bar{D}^{*} \Sigma_c$ are constructed based on K-matrix with the Chew-Mandelstam function. We build the $\Lambda_b\to J/\Psi p K^-$ amplitude according to the Au-Morgan-Pennington method. The event shape is fitted and the decay width of $\Lambda_b\to J/\Psi p K^-$ is used to constrain the parameters, too. With the amplitudes we extract out the poles and their residues. Our amplitude and pole analysis suggest that the $P_c(4312)$ should be $\bar{D}\Sigma_c$ molecule, the $P_c(4440)$ could be an S-wave compact pentaquark state, and the structure around $P_c(4457)$ is caused by the cusp effect. The future experimental measurement of the decays of $\Lambda_b\to \bar{D}\Sigma_c K^-$ and $\Lambda_b\to \bar{D}^*\Sigma_c K^-$ would further help to study the nature of these resonances.Comment: updated to the published versio

Triaqua­(1,10-phenanthroline-2,9-dicarboxyl­ato)cobalt(II) dihydrate

The title compound, [Co(C14H6N2O4)(H2O)3]·2H2O, has two­fold crystallographic symmetry. The CoII atom is in a distorted penta­gonal-bipyramidal coordination environment with two N atoms and two O atoms from a tetradentate 1,10-phenanthroline-2,9-dicarboxyl­ate ligand and one O atom from a water mol­ecule forming the penta­gonal plane, and two O atoms from two water mol­ecules occupying axial positions. In the crystal, adjacent mol­ecules are linked by O—H⋯O hydrogen bonds, forming a three-dimensional network

Reproductive traits and mandibular gland pheromone of anarchistic honey bee workers Apis mellifera occurring in China

International audienceAbstractIn honey bee colonies, workers, in particular of “anarchistic” lineages, can activate their ovaries and lay eggs, even in the presence of the queen. We identified three queenright colonies showing typical signs of worker reproduction. To characterize this new lineage, we extracted the mandibular gland and analyzed it using gas chromatography. The total amounts of the five main components of the mandibular gland, namely methyl p-hydroxyben-zoate (HOB), 9-oxo-2(E)-decenoic acid (9-ODA), (S)-9-hydroxy-(E)-2-decenoic acid (9-HDA), 10-HDA, and 10-hydroxyde-canoic acid (10-HDAA) were significantly higher in the mandibular gland profiles of workers with activated ovaries (AWs, 8.88 ± 1.71 μg) compared to workers with inactivated ovaries (IAWs, 4.00 ± 2.09 μg). Furthermore, the chemical profiles of IAWs were dominated by the “worker substances” 10-HDA (34.64 ± 8.19 %) and its precursor 10-HDAA (22.88 ± 4.95 %), while the chemical profiles in AWs were dominated by the precursor of the queen substance 9-HDA (40.04 ± 7.55 %). The ratios of two precursor substances 10-HDAA/9-HDA of IAWs were more worker like (>1.0) whereas AWs were more queen like (≤1.0). These results suggest that the mandibular pheromones of anarchistic workers resemble a more queen-like reproductive active profile and that these workers may represent a reversion to a more basal reproductive phenotype

The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer

<p>Abstract</p> <p>Background</p> <p>Although an abundance of evidence has indicated that tumor-associated macrophages (TAMs) are associated with a favorable prognosis in patients with colon cancer, it is still unknown how TAMs exert a protective effect. This study examined whether TAMs are involved in hepatic metastasis of colon cancer.</p> <p>Materials and methods</p> <p>One hundred and sixty cases of pathologically-confirmed specimens were obtained from colon carcinoma patients with TNM stage IIIB and IV between January 1997 and July 2004 at the Cancer Center of Sun Yat-Sen University. The density of macrophages in the invasive front (CD68TF_Hotspot) was scored with an immunohistochemical assay. The relationship between the CD68TF_Hotspotand the clinicopathologic parameters, the potential of hepatic metastasis, and the 5-year survival rate were analyzed.</p> <p>Results</p> <p>TAMs were associated with the incidence of hepatic metastasis and the 5-year survival rate in patients with colon cancers. Both univariate and multivariate analyses revealed that the CD68TF_Hotspotwas independently prognostic of survival. A higher 5-year survival rate among patients with stage IIIB after radical resection occurred in patients with a higher macrophage infiltration in the invasive front (81.0%) than in those with a lower macrophage infiltration (48.6%). Most importantly, the CD68TF_Hotspotwas associated with both the potential of hepatic metastasis and the interval between colon resection and the occurrence of hepatic metastasis.</p> <p>Conclusion</p> <p>This study showed evidence that TAMs infiltrated in the invasive front are associated with improvement in both hepatic metastasis and overall survival in colon cancer, implying that TAMs have protective potential in colon cancers and might serve as a novel therapeutic target.</p

Exercise preference in stroke survivors: a concept analysis

BackgroundExercise preference in stroke survivors is related to their adherence to long-term rehabilitation regimen and functional recovery. Although explored recently, the term exercise preference still lacks a clear definition.ObjectiveThe aim of this study is to conceptualize exercise preference in stroke survivors.MethodsThe Walker and Avant method was applied as a framework for the conceptual analysis of exercise preference. Data from 34 publications were collected using seven databases (PubMed, Web of Science, Embase, CINAHL, CNKI, Wanfang Data, and CBM) and applied in the analysis. The search period was from the inception of the database to April 30, 2023.ResultsExercise preference in stroke survivors was defined according to four attributes: priority of choice, behavioral tendency, affective priming, and patience in adherence. The common antecedents of the concept of exercise preference in stroke survivors were classified into patient-related, therapy-related, and environmental-related categories and the consequences were classified into three categories: patient-related, rehabilitation provider–related, and rehabilitation service system–related.ConclusionExercise preference in stroke survivors refers to the patient’s choice, tendency, affective response, and attitude toward engagement in the recommended rehabilitation regimen. It is beneficial for understanding the essential attributes of exercise preference in stroke survivors by clarifying the concept. In addition, it will facilitate the development of instruments for assessing exercise preference in stroke survivors and the construction of theory-based intervention programs that can improve adherence to exercise rehabilitation

The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

<p>Abstract</p> <p>Background</p> <p>One of the putative mechanisms of tumor immune escape is based on the hypothesis that carcinomas actively create an immunosuppressed state via the expression of indoleamine 2,3-dioxygenase (IDO), both in the cancer cells and in the immune cells among the tumor-draining lymph nodes (TDLN). In an attempt to verify this hypothesis, the patterns of expression of IDO in the cancer cells and the immune cells among colon cancers were examined.</p> <p>Methods</p> <p>Seventy-one cases of pathologically-confirmed colon cancer tissues matched with adjacent non-cancerous tissues, lymph node metastases, and TDLN without metastases were collected at the Sun Yat-sen Cancer Center between January 2000 and December 2000. The expression of IDO and Bin1, an IDO regulator, was determined with an immunohistochemical assay. The association between IDO or Bin1 expression and TNM stages and the 5-year survival rate in colon cancer patients was analyzed.</p> <p>Results</p> <p>IDO and Bin1 were detected in the cytoplasm of cancer cells and normal epithelium. In primary colon cancer, the strong expression of IDO existed in 9/71 cases (12.7%), while the strong expression of Bin1 existed in 33/71 cases (46.5%). However, similar staining of IDO and Bin1 existed in the adjacent non-cancerous tissues. Among the 41 cases with primary colon tumor and lymph node metastases, decreased expression of IDO was documented in the lymph node metastases. Furthermore, among the TDLN without metastases, a higher density of IDO⁺cells was documented in 21/60 cases (35%). Both univariate and multivariate analyses revealed that the density of IDO⁺cells in TDLN was an independent prognostic factor. The patients with a higher density of IDO⁺cells in TDLN had a lower 5-year survival rate (37.5%) than the cells with a lower density (73.1%).</p> <p>Conclusion</p> <p>This study demonstrated paradoxical patterns of expression of IDO in colon cancer. The high density IDO⁺cells existed in TDLN and IDO was down-regulated in lymph nodes with metastases, implying that IDO in tumor and immune cells functions differently.</p

Parallel momentum distribution of the 28^{28}Si fragments from 29^{29}P

Distribution of the parallel momentum of $^{28}$Si fragments from the breakup of 30.7 MeV/nucleon $^{29}$P has been measured on C targets. The distribution has the FWHM with the value of 110.5 $\pm$ 23.5 MeV/c which is consistent quantitatively with Galuber model calculation assuming by a valence proton in $^{29}$P. The density distribution is also predicted by Skyrme-Hartree-Fock calculation. Results show that there might exist the proton-skin structure in $^{29}$P.Comment: 4 pages, 4 figure

Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine

Whole tumor cell lysates (TCL) have been implemented as tumor antigens for cancer vaccine development, although clinical outcomes of TCL-based antitumor immunotherapy remain unsatisfactory. In order to improve the efficacy of TCL-based vaccines, biomaterials have been employed to enhance antigen delivery and presentation. Here, we have developed chitosan nanoparticles (CTS NPs) with surface mannose (Man) moieties for specific dendritic cells (DCs) targeting (Man-CTS NPs). The Man-CTS NPs were then loaded with TCL generated from B16 melanoma cells (Man-CTS-TCL NPs) for in vitro and in vivo assessment. Potency of the Man-CTS-TCL NPs as cancer vaccine was also assessed in vivo by immunization of mice with Man-CTS-TCL NPs followed by re-challenge with B16 melanoma cell inoculation. We have shown here that Man-CTS-TCL NPs promote bone marrow-derived dendritic cells (BMDCs) maturation and antigen presentation in vitro. In vivo evaluation further demonstrated that the Man-CTS-TCL NPs were readily taken up by endogenous DCs within the draining lymph node (DLN) following subcutaneous administration accompanied by increasing in serum IFN-γ and IL-4 levels. Tumor growth was also significantly delayed in mice primed with Man-CTS-TCL NPs vaccine, attributable at least in part to cytotoxic T lymphocytes response. Moreover, Man-CTS-TCL NPs vaccine also exhibited therapeutic effects in mice with melanoma. Thus, we report here the Man-CTS-TCL NPs as effective anti-tumor vaccine for cancer immunotherapy